Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
Rhea-AI Summary
Relmada Therapeutics (Nasdaq: RLMD) said it will report third quarter 2025 financial results and recent business progress on Thursday, November 13, 2025 at 4:30 PM ET via a conference call and webcast.
Participant dial-in numbers are US: 1-877-407-0792 and International: 1-201-689-8263. A webcast replay will be available in the Investors section at https://www.relmada.com/investors/ir-calendar.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, RLMD gained 1.53%, reflecting a mild positive market reaction. Argus tracked a trough of -8.0% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $90M at that time.
Data tracked by StockTitan Argus on the day of publication.
CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress.
Conference Call and Webcast Information:
- Date: Thursday, November 13, 2025 at 4:30 PM ET
- Participant Dial-in (US): 1-877-407-0792
- Participant Dial-in (International): 1-201-689-8263
- Webcast Access: Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
FAQ
When will Relmada Therapeutics (RLMD) release its Q3 2025 financial results?
How can investors join the Relmada (RLMD) Q3 2025 conference call and webcast?
Where will the Relmada (RLMD) webcast replay for the November 13, 2025 call be posted?
What topics will Relmada (RLMD) cover during the November 13, 2025 call?
What time should shareholders dial in for Relmada's (RLMD) Q3 2025 call in Eastern Time?
Will international participants be able to access Relmada (RLMD) Q3 2025 call?
